VistaGen Therapeutics Inc (VTGN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Shawn K. Singh
Employees:
40
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA 94080
650-577-3600

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system. The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder.

Data derived from most recent annual or quarterly report
Market Cap 30.925 Million Shares Outstanding219.326 Million Avg 30-day Volume 3.747 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.05
Price to Revenue0.0 Debt to Equity0.0207 EBITDA-48.097 Million
Price to Book Value1.0927 Operating Margin0.0 Enterprise Value-2.02 Million
Current Ratio6.078 EPS Growth0 Quick Ratio5.84
1 Yr BETA 1.8243 52-week High/Low 1.2 / 0.08 Profit Margin0.0
Operating Cash Flow Growth-407.1531 Altman Z-Score-17.8584 Free Cash Flow to Firm -40.519 Million
Earnings Report2023-06-22
View SEC Filings from VTGN instead.

View recent insider trading info

VistaGen Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding VTGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding VTGN

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-03 by DOTSON JERROLD DUANE
  • 4: filed on 2023-01-03 by SINGH SHAWN
  • 4: filed on 2022-08-22 by GIN JERRY B
  • 4: filed on 2022-08-19 by ADLER REID G.
  • 4: filed on 2022-08-18 by SINGH SHAWN
  • 4: filed on 2022-07-15 by DOTSON JERROLD DUANE
  • 4: filed on 2022-07-15 by SINGH SHAWN
  • 4: filed on 2022-07-15 by SMITH MARK ALAN
  • 4: filed on 2022-07-14 by SHAH NIMISH P
  • 3: filed on 2022-07-08 by SHAH NIMISH P

    • Events (8k)

  • 8-K: filed on 2023-06-01:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-27:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-19:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-06:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-30:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-23:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-07:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-02:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DOTSON JERROLD DUANE VP, CFO AND SECRETARY

    • Officer
    		 105,111 2022-12-30 2

    SINGH SHAWN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 785,232 2022-12-30 3

    GIN JERRY B

    • Director
    		 200,000 2022-08-18 1

    ADLER REID G. CHIEF LEGAL OFFICER

    • Officer
    		 334,629 2022-08-17 1

    VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.

    VHCP CO-INVESTMENT HOLDINGS II, LLC

    VHCP MANAGEMENT II, LLC

    VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P.

    VHCP CO-INVESTMENT HOLDINGS III, LLC

    VHCP MANAGEMENT III, LLC

    VENROCK HEALTHCARE CAPITAL PARTNERS EG, L.P.

    VHCP MANAGEMENT EG, LLC

    KOH BONG Y

    SHAH NIMISH P

    • 10% Owner
    		 20,637,286 2022-07-12 1

    SMITH MARK ALAN CHIEF MEDICAL OFFICER

    • Officer
    		 19,915 2022-06-30 1

    SAXE JON S

    • Director
    		 155,751 2022-03-01 0

    CUNNINGHAM ANN MICHELLE CHIEF COMMERCIAL OFFICER

    • Officer
    • Director
    		 150,000 2022-03-01 0

    CURLEY JOANNE

    • Director
    		 100,000 2022-03-01 0

    ROTUNNO MARY L.

    • Director
    		 100,000 2022-03-01 0

    FITZPATRICK MARGARET M

    • Director
    		 100,000 2022-03-01 0

    SNODGRASS H. RALPH PRES./CHIEF SCIENTIFIC OFFICER

    • Officer
    		 98,859 2021-12-31 0

    UNDERDOWN BRIAN J.

    • Director
    		 0 2021-03-19 0

    GINSKI MARK J SENIOR VP, HEAD OF CMC

    • Officer
    		 0 2021-02-01 0

    MCPARTLAND MARK A. VP CORPORATE DEVELOPMENT

    • Officer
    		 150,000 2020-12-30 0

    PLATINUM LONG TERM GROWTH VII, LLC

    • 10% Owner
    		 No longer subject to file 2011-12-22 0

    CATO HOLDING CO

    • 10% Owner
    		 3,310,836 2011-12-15 0

    CATO ALLEN EASLEY

    • 10% Owner
    		 452,621 2011-12-15 0

    RICE A. FRANKLIN CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2011-05-11 0

    JONES STEPHANIE PRESIDENT

    • Officer
    • Director
    • 10% Owner
    		 17,897 2011-05-09 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 22:15:04 UTC 0.2678 4.7922 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 21:45:04 UTC 0.2678 4.7922 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 21:15:04 UTC 0.2579 4.8021 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 20:45:03 UTC 0.2579 4.8021 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 20:15:05 UTC 0.2579 4.8021 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 19:45:04 UTC 0.2579 4.8021 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 19:15:04 UTC 0.2579 4.8021 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 18:45:04 UTC 2.3675 2.6925 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 18:15:04 UTC 2.3675 2.6925 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 17:45:03 UTC 2.3675 2.6925 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 17:15:04 UTC 2.3675 2.6925 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 16:45:03 UTC 2.3499 2.7201 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 16:15:04 UTC 2.3499 2.7201 150000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 15:45:04 UTC 2.3499 2.7201 150000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 15:15:03 UTC 2.3499 2.7201 150000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 14:45:04 UTC 2.3499 2.7201 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 14:15:03 UTC 2.3499 2.7201 100000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 13:45:03 UTC -1.7153 6.7853 90000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 13:15:04 UTC -1.7153 6.7853 90000
    VISTAGEN THERAPEUTICS INC VTGN 2023-06-02 12:45:03 UTC -1.7153 6.7853 90000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund VTGN -20100.0 shares, $-2506.47 2023-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments